DEBBANE RAYMOND
DEBBANE RAYMOND's purchase track record
How the stock did after each of DEBBANE RAYMOND's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/23/2026 | LXRX | $150K | +36.4% | +53.6% | +11.9% |
| 2/13/2026 | LXRX | $573K | +70.2% | +77.1% | +13.9% |
| 10/10/2023 | LXRX | $1.10M | +32.1% | +84.8% | +19.5% |
| 11/10/2022 | WW | $320K | pending | pending | — |
| 8/1/2022 | LXRX | $2.46M | -9.3% | -8.4% | -2.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
WW International Reports Momentum in GLP-1 Care and Cash Flow. WW International is highlighting a potential cash flow turnaround driven by growing momentum in its GLP-1 care services. This development is relevant to the company's broader strategy as it seeks to adapt to changes in the weight management market. The stock currently trades near its support level, with analysts maintaining a higher average price target than the current market price.
Transaction History
| LXRX | ▲ Buy | Option Exercise | 89,312 | $0 | 6/3/2026 | View on chart |
| LXRX | ▲ Buy | Open Market | 2,000 | $3K | 2/25/2026 | View on chart |
| LXRX | ▲ Buy | Open Market | 100,000 | $147K | 2/23/2026 | View on chart |
| LXRX | ▲ Buy | Open Market | 100,000 | $148K | 2/20/2026 | View on chart |
| LXRX | ▲ Buy | Open Market | 50,000 | $72K | 2/19/2026 | View on chart |
| LXRX | ▲ Buy | Open Market | 133,688 | $176K | 2/18/2026 | View on chart |
| LXRX | ▲ Buy | Open Market | 76,857 | $101K | 2/17/2026 | View on chart |
| LXRX | ▲ Buy | Open Market | 57,952 | $76K | 2/13/2026 | View on chart |
| LXRX | ▲ Buy | Option Exercise | 36,810 | $0 | 5/13/2025 | View on chart |
| LXRX | ▲ Buy | Option Exercise | 8,032 | $0 | 4/28/2024 | View on chart |
| LXRX | ▲ Buy | Open Market | 148,820 | $154K | 10/12/2023 | View on chart |
| LXRX | ▲ Buy | Open Market | 342,874 | $371K | 10/11/2023 | View on chart |
| LXRX | ▲ Buy | Open Market | 508,306 | $579K | 10/10/2023 | View on chart |
| LXRX | ▲ Buy | Option Exercise | 9,302 | $0 | 5/21/2023 | View on chart |
| WW | ▲ Buy | Grant | 835 | $0 | 5/9/2023 | View on chart |
| WW | ▲ Buy | Grant | 2,053 | $0 | 4/3/2023 | View on chart |
| WW | ▲ Buy | Grant | 5,067 | $0 | 1/2/2023 | View on chart |
| WW | ▲ Buy | Open Market | 75,000 | $320K | 11/10/2022 | View on chart |
| WW | ▲ Buy | Grant | 4,595 | $0 | 10/3/2022 | View on chart |
| LXRX | ▲ Buy | Open Market | 982,600 | $2.5M | 8/1/2022 | View on chart |
| WW | ▲ Buy | Grant | 2,745 | $0 | 7/4/2022 | View on chart |
| LXRX | ▲ Buy | Option Exercise | 4,024 | $0 | 4/30/2022 | View on chart |
| WW | ▲ Buy | Grant | 1,797 | $0 | 4/4/2022 | View on chart |
| WW | ▲ Buy | Grant | 1,179 | $19K | 1/3/2022 | View on chart |
| WW | ▲ Buy | Grant | 998 | $19K | 10/4/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Lexicon Reports Consistent Heart Failure Drug Data in New Analysis
Lexicon Pharmaceuticals announced new analysis from the SOLOIST-WHF trial showing its drug sotagliflozin produced consistent results in patients with worsening heart failure across different baseline blood pressure levels. This post hoc analysis reinforces findings from the original trial studying hospitalized heart failure patients. The company also confirmed participation in three upcoming investor conferences, a routine corporate engagement practice. The data announcement represents the substantive news for this period.
Lexicon Reports Consistent Heart Failure Drug Data in New Analysis. Lexicon Pharmaceuticals announced new analysis from the SOLOIST-WHF trial showing its drug sotagliflozin produced consistent results in patients with worsening heart failure across different baseline blood pressure levels. This post hoc analysis reinforces findings from the original trial studying hospitalized heart failure patients. The company also confirmed participation in three upcoming investor conferences, a routine corporate engagement practice. The data announcement represents the substantive news for this period.